Review began 02/24/2023 review ended 03/09/2023 published 03/15/2023 © copyright

HIGHLIGHTS

• who: Abeparvovec (Zolgensma and colleagues from the School of Medicine, Saint Vincent and Grenadines, VCT Pharmacology, Saint James School of Medicine, Saint have published the paper: Review began 02/24/2023 Review ended 03/09/2023 Published 03/15/2023 u00a9 Copyright, in the Journal: (JOURNAL) of March/15,/2023
• what: The aim of the study is to review the safety and efficacy of a novel gene therapy onasemnogene (Zolgensma) for SMA and assess current challenges for gene therapy.

SUMMARY

And Background SMA is a genetic disease that causes weakness and . . .

 



If you want to have access to all the content you need to log in!

Thanks :)

Username or E-mail:

If you don't have an account, you can create one here.